• Galena Biopharma Inc., of Portland, Ore., presented a poster at the Society for Immunotherapy of Cancer Conference in National Harbor, Md., detailing results of the Phase I portion of its trial for the folate-binding protein vaccine, a cancer immunotherapy product in development for patients with HLA A2-positive cancers.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter